US2013178529A1PendingUtilityA1

Ibuprofen compositions and methods of making same

46
Assignee: RECORDATI RARE DISEASES INCPriority: Mar 6, 2011Filed: Mar 4, 2013Published: Jul 11, 2013
Est. expiryMar 6, 2031(~4.6 yrs left)· nominal 20-yr term from priority
Inventors:Aravind Krishna
A61K 9/0019A61K 31/205
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides an improved ibuprofen lysine pharmaceutical composition and a process for preparing the same.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 ) A pharmaceutical composition comprising:
 a) an alkylammonium salt of ibuprofen selected from the group consisting of R-ibuprofen, S-ibuprofen and R,S-ibuprofen;   b) an aqueous, or a non-aqueous solvent;   c) optionally an absence of preservative; and   d) optionally the presence of an excipient; wherein   
       the composition is in a unit dosage form in a vial, ampoule, blister pack, or prefillable delivery system, said vial, ampoule, blister pack or prefillable delivery system comprises an inert polymeric material. 
     
     
         16 ) The pharmaceutical composition of  claim 15 , wherein the alkylammonium salt is selected from a group consisting of d,l-lysine, l-lysine, d-lysine, tromethamine, and meglumine. 
     
     
         17 ) The pharmaceutical composition of  claim 15 , wherein the alkylammonium salt is selected from the group considering of d,l-lysine, l-lysine, d-lysine. 
     
     
         18 ) The pharmaceutical composition of  claim 15 , wherein the vial, ampoule, blister pack, or prefillable delivery system is inert such that the pharmaceutical composition has less than about 5 μg/L of ibuprofen aluminum salt precipitate. 
     
     
         19 ) The pharmaceutical composition of  claim 15 , wherein the liquid unit dosage form is a mixture selected from the group consisting of a solution, suspension, dispersion and emulsion. 
     
     
         20 ) The pharmaceutical composition of  claim 15 , wherein the composition can be administered parenterally. 
     
     
         21 ) The pharmaceutical composition of  claim 15 , wherein there is an absence of preservative. 
     
     
         22 ) The pharmaceutical composition of  claim 15 , wherein there is a presence of excipient. 
     
     
         23 ) The pharmaceutical composition of  claim 15 , wherein the polymeric material is a cyclic olefin polymer.

Join the waitlist — get patent alerts

Track US2013178529A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.